Lipid Accumulation Product Index as a Marker of Metabolic Syndrome in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta‐Analysis
Endocrinology, Diabetes & Metabolism · 2025-09 · 8 (5)
DOI: 10.1002/edm2.70078 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 04.09.2025. Verfasst von Seyed Arsalan Seyedi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Imam Khomeini Hospital, Tehran, Iran. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Metabolic Syndrome, Lipid Accumulation Product. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Lipid accumulation product (LAP) index is a measure of lipid toxicity based on triglyceride and waist circumference. The aim of the current study is to explore the relationship between LAP index and metabolic syndrome (MetS) among women with polycystic ovary syndrome (PCOS) in a systematic review and meta‐analysis.
Methods
Web of Science, Embase and PubMed online databases were systematically searched for studies investigating the relationship between LAP index and MetS in PCOS. Ten observational studies, including 12 populations with 2957 individuals, were identified for analysis. Mean difference and bivariate diagnostic test accuracy (DTA) meta‐analyses were performed.
Results
A significant LAP index difference of 49.17 was found in women with PCOS with and without MetS (95% CI [40.57, 57.77]). By DTA meta‐analysis, the pooled sensitivity and specificity of LAP index for MetS detection were 87% ( I 2 78%, 95% CI [80%, 92%]) and 88% ( I 2 78%, 95% CI [83%, 92%]), respectively, with area under the curve of 0.94 (95% CI [0.91, 0.96]).
Conclusion
The LAP index is an affordable, specific and sensitive marker for MetS and may be considered a pragmatic tool for MetS detection among patients with PCOS, particularly those with an insulin resistance endotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Imam Khomeini Hospital, Tehran, Iran.
- School of Pharmacy and Pharmaceutical Sciences, Islamic Azad University of Tehran Medical Sciences, Tehran, Iran.
- Faculty of Pharmacy, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran.
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Universal Scientific Education and Research Network (USERN), Tehran, Iran.
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Seyed Arsalan Seyedi, Dorsa Alizadegan, Alireza Esteghamati
Zitieren
APA
Seyedi, S. A., Nabipoorashrafi, S. A., Amin Afshari, S., Mansouri, A., Alizadegan, D., Hobaby, S., Esmaeilpur Abianeh, F., Mechanick, J. I., & Esteghamati, A. (2025). Lipid Accumulation Product Index as a Marker of Metabolic Syndrome in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta‐Analysis. Endocrinology, Diabetes & Metabolism, 8(5). https://doi.org/10.1002/edm2.70078
Vancouver
Seyedi SA, Nabipoorashrafi SA, Amin Afshari S, Mansouri A, Alizadegan D, Hobaby S, et al. Lipid Accumulation Product Index as a Marker of Metabolic Syndrome in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta‐Analysis. Endocrinology, Diabetes & Metabolism. 2025;8(5). doi:10.1002/edm2.70078
BibTeX
@article{Seyedi2025,
author = {Seyedi, Seyed Arsalan and Nabipoorashrafi, Seyed Ali and Amin Afshari, Samira and Mansouri, Afsoun and Alizadegan, Dorsa and Hobaby, Sara and Esmaeilpur Abianeh, Fatemeh and Mechanick, Jeffrey I and Esteghamati, Alireza},
title = {Lipid Accumulation Product Index as a Marker of Metabolic Syndrome in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta‐Analysis},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2025},
volume = {8},
number = {5},
doi = {10.1002/edm2.70078}
}
EUVIMED